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All itch, no pain
Chronic itch, which results from skin diseases as well as 
more systemic conditions, is estimated to affect 10–20% of 
the population at some point during their lives. Although 
some forms of itch are treatable with antihistamines, anoth-
er subset of itch is chronic and resistant to such treatment. 
Morita and colleagues identified the peripheral serotonin 
(5-hydroxytryptamine) receptor (HTR7) in chronic itch, 
based on the correlation between itch behavior and HTR7 
gene expression in susceptible mouse strains. Further 
examination revealed that this itch transducer is expressed 
in a subset of small-diameter skin sensory neurons, which 
are known to mediate itch and/or pain, and specifically 
triggers itch but not pain via the inflammatory ion chan-
nel TRPA1. These investigators found that HTR7 medi-
ates serotonergic itch and that both HTR7 and TRPA1 are 
required for the development of chronic itch in a mouse 
model of atopic dermatitis. Specifically, these findings will 
prove valuable for clinical investigations of antagonists 
to halt chronic itch due to atopic dermatitis and selective 
serotonin reuptake inhibitors. (Neuron 87:124–38, 2015) 
Selected by M. Amagai
A little Aire time
The intermediate filament protein keratin 17 (K17) exhib-
its increased expression in inflammatory skin diseases as 
well as in epithelia-derived tumors. Hobbs and colleagues 
recently reported that loss of Krt17 delays Gli2-induced 
tumorigenesis in mouse skin and attenuates key proinflam-
matory signaling molecules. These studies also identified a 
novel role for the autoimmune regulator Aire in keratino-
cytes, especially during skin tumorigenesis. Expression of 
Aire was found to be dependent on K17. Additionally, Aire 
physically interacts with K17 in the nucleus, and both fac-
tors are bound to the same promoter regions of select tar-
get genes that exhibit K17-dependent expression. Together, 
these findings suggest that K17 upregulation is an early 
inflammatory event in diseased epithelia and that Aire pro-
motes gene expression in keratinocytes and skin undergo-
ing acute inflammation or tumorigenesis in partnership with 
K17. (Nat Genet 47:933–8, 2015) Selected by L. Goldsmith
Questioning the drivers of transformation
To study the burden, mutational processes, and clonal 
structure of somatic mutations in normal sun-exposed eye-
lid skin biopsies, Martincorena and colleagues sequenced 
the coding exons of 74 cancer-related genes in 234 biop-
sies from four individuals. The burden of somatic mutations 
in normal skin cells (2–6 mutations/Mb/cell) was similar to 
that reported for many cancers. Furthermore, pervasive pos-
itive selection of somatic mutations in normal skin was sim-
ilar to that observed in squamous cell carcinoma, and such 
positively selected mutations were identified in 18–32% of 
normal skin cells with a density of 140 driver mutations/
cm2 and 0.27 driver mutations/cell. Interestingly, clones 
harboring two or three driver mutations were detected, yet 
these clones had not acquired malignant potential, raising 
the question of what specific events, aside from acquisi-
tion of driver mutations, are required to convey transform-
ing potential to normal cells. (Science 348:880–6, 2015) 
Selected by T. Schwarz
Secrets of secretagogues
Mast cells are the primary effectors in allergic reactions 
via IgE antibody activation; however, this immune cell 
type also responds in an antibody-independent manner to 
cationic substances, termed basic secretagogues, which 
include inflammatory peptides and drugs associated with 
allergic-type reactions. Following an extensive search, 
McNeil and colleagues identified Mrgprb2 as the single 
receptor responsible for activation of mouse mast cells by 
basic secretagogues because histamine release, inflamma-
tion, and airway contraction were minimized in Mrgprb2-
deficient mice. Examination of drug-induced reactions, 
which clinically appear to be allergic in nature yet do not 
correlate well with IgE titers, revealed that cationic drugs 
associated with injection site reactions activated mast cells 
in a Mrgprb2-dependent manner, suggesting that targeting 
MRGPRX2, the receptor ortholog in humans, may alleviate 
such allergic reactions in patients. Furthermore, this recep-
tor is targeted by many small-molecule drugs that have been 
associated with pseudo-allergic reactions, highlighting 
the relevance of these findings for targeting MRGPRX2 for 
the reduction of drug-induced adverse reactions. (Nature 
519:237–41, 2015) Selected by T. Schwarz
Tale of two modifications
Intercellular adhesive junctions involve desmosomes that 
confer structural integrity to tissues such as skin and heart 
and are required to establish cell polarity and cell migration 
and to facilitate embryo and tissue development. Genetic 
mutations in desmoplakin (DP), a protein involved in 
anchoring of the keratin and desmin intermediate filament 
(IF) cytoskeletons to the plasma membrane–associated des-
mosomal plaques, result in skin disease as well as arrhyth-
mogenic cardiomyopathy. Posttranslational modifications of 
DP have been suggested to regulate cytoskeletal organiza-
tion during development, tissue remodeling, and disease, 
and recently, Albrecht and colleagues demonstrated that 
arginine methylation and processive phosphorylation of DP 
are critical for DP–IF cytoskeletal dynamics. Recruitment 
of glycogen synthase kinase 3 and protein arginine meth-
yltransferase 1 to the DP C-terminal tail regulated DP–IF 
complexes in establishment of cell–cell adhesion. In the 
presence of an arrhythmogenic cardiomyopathy–causing 
mutation in DP in an arginine methylation site, such des-
mosome regulation signaling machinery is disrupted, lead-
ing to disease. (J Cell Biol 208:597–612, 2015) Selected by 
A. Kowalczyk
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